21-07-2022, 08:58 AM
A fourth vaccination offered a marginal increase in effectiveness over the third dose (received ≥ 84 days before) against infection, symptomatic infection, and severe outcomes.
But the marginal effectiveness was lower if the third dose was administered less than 84 days previously. This broadly suggested the three-month interval between the third and fourth doses.
Vaccine effectiveness against infection, symptomatic infection, and severe outcomes was higher for second booster recipients than triple-vaccinated residents.
In conclusion, a fourth COVID-19 mRNA vaccine increased protection against the measured outcomes among LTC residents during the Omicron-dominant phase, albeit the duration of protection needs to be investigated.
https://www.news-medical.net/news/202207...riant.aspx
But the marginal effectiveness was lower if the third dose was administered less than 84 days previously. This broadly suggested the three-month interval between the third and fourth doses.
Vaccine effectiveness against infection, symptomatic infection, and severe outcomes was higher for second booster recipients than triple-vaccinated residents.
In conclusion, a fourth COVID-19 mRNA vaccine increased protection against the measured outcomes among LTC residents during the Omicron-dominant phase, albeit the duration of protection needs to be investigated.
https://www.news-medical.net/news/202207...riant.aspx